South Korea · Delayed Price · Currency is KRW Regulus Therapeutics Statistics
Total Valuation
KOSDAQ:476040 has a market cap or net worth of KRW 199.34 billion. The enterprise value is 191.22 billion.
| Market Cap | 199.34B |
| Enterprise Value | 191.22B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
KOSDAQ:476040 has 6.55 million shares outstanding.
| Current Share Class | 6.55M |
| Shares Outstanding | 6.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 29.02% |
| Owned by Institutions (%) | 19.33% |
| Float | 3.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 102.06 |
| PB Ratio | 13.04 |
| P/TBV Ratio | 13.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.00 |
| EV / Sales | 97.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -19.50 |
Financial Position
The company has a current ratio of 3.35, with a Debt / Equity ratio of 0.53.
| Current Ratio | 3.35 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.83 |
| Interest Coverage | -3.84 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -26.08% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -58.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 34,240.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 45.47 |
| Average Volume (20 Days) | 448,479 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KOSDAQ:476040 had revenue of KRW 1.95 billion and -11.25 billion in losses. Loss per share was -2,690.83.
| Revenue | 1.95B |
| Gross Profit | 1.91B |
| Operating Income | -12.23B |
| Pretax Income | -11.54B |
| Net Income | -11.25B |
| EBITDA | -10.93B |
| EBIT | -12.23B |
| Loss Per Share | -2,690.83 |
Balance Sheet
The company has 16.20 billion in cash and 8.09 billion in debt, giving a net cash position of 8.11 billion or 1,238.37 per share.
| Cash & Cash Equivalents | 16.20B |
| Total Debt | 8.09B |
| Net Cash | 8.11B |
| Net Cash Per Share | 1,238.37 |
| Equity (Book Value) | 15.29B |
| Book Value Per Share | 2,905.63 |
| Working Capital | 11.85B |
Cash Flow
In the last 12 months, operating cash flow was -9.14 billion and capital expenditures -667.07 million, giving a free cash flow of -9.81 billion.
| Operating Cash Flow | -9.14B |
| Capital Expenditures | -667.07M |
| Free Cash Flow | -9.81B |
| FCF Per Share | -1,498.14 |
Margins
| Gross Margin | 97.81% |
| Operating Margin | -626.38% |
| Pretax Margin | -590.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KOSDAQ:476040 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -5.64% |
| FCF Yield | -4.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KOSDAQ:476040 has an Altman Z-Score of -5.89 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.89 |
| Piotroski F-Score | 1 |